Sort   by:  
 Page size 
ProteomicsStructural surfaceomics of myeloma models to identify tumor-specific protein conformations
Proteins at the cell surface are promising targets for cancer immunotherapies. While standard surface proteomics can be powerful for target discovery, even more fruitful is identifying cancer-specific surface protein features. To this end, we recently described a technology to identify cancer-specif...
ORGANISM(S): Homo sapiens (Human) 
2025-10-20 | PXD059495 | Pride
Cell surface proteomics  xl-ms  crosslinking mass spectrometry  structural biology  protein structure 
ProteomicsMicro cell surface proteomics myeloma
The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-cell ...
ORGANISM(S): Homo sapiens (Human) 
2022-05-27 | PXD022553 | Pride
Cell surface Plasma cell Multiple myeloma 
ProteomicsFunctional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma
CD38 is a surface ectoenzyme expressed at high levels on myeloma plasma cells and is the target for the monoclonal antibodies (mAbs) daratumumab and isatuximab. CD38 density on tumor cells is an important determinant of mAb efficacy while CD38 is lost after mAb treatment. Several small molecules hav...
ORGANISM(S): Homo sapiens (Human) 
2021-07-29 | PXD027594 | Pride
Crispr-interference Atra Myeloma surfaceome Azacytidine Cd38 Panobinostat Daratumamab Phosphoproteomics 
UnknownThe surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Not available
S-EPMC9287322 | biostudies-literature
ProteomicsDefining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance
The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-cell ...
ORGANISM(S): Homo sapiens (Human) 
2022-05-27 | PXD022482 | Pride
Cell surface Plasma cell Multiple myeloma Immunotherapy 
ProteomicsPrimary Myeloma Proteomics using Micro IST method
The myeloma cell surface proteome (“surfaceome�) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-c...
ORGANISM(S): Homo sapiens (Human) 
2022-05-27 | PXD032031 | Pride
Myeloma 
TranscriptomicsDefining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance
The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-cell ...
ORGANISM(S): Homo sapiens 
2021-12-10 | GSE160572 | GEO
ProteomicsMapping the Multiple Myeloma cell surface proteome for immune target discovery
Multiple myeloma (MM) is an incurable malignancy of plasma cells. Immunotherapy is a promising treatment option that relies on the identification of biologically and therapeutically relevant cell surface targets. We unbiasedly mapped the surfaceome of 7 MM cell lines and 904 primary MM patients bea...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2021-11-19 | MSV000088419 | MassIVE
UnknownFunctional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma.
Not available
S-EPMC12093323 | biostudies-literature
GenomicsDefining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance
Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance
PRJNA673624 | ENA
Sort   by:  
 Page size